Abstract:Chimeric antigen receptors T (CAR-T) cell therapy of cancer is a rapidly evolving field. It has been shown to be remarkably effective in cases of hematological malignancies, and its approval by the FDA has significantly increased the enthusiasm for wide clinical usage and development of novel CAR-T therapies. However, it has also challenged physicians and investigators to recognize and deal with treatment-associated toxicities. A total of 2592 patients were included from 84 eligible studies that were systematically searched and reviewed from the databases of PubMed, de, the American Society of Hematology and the Cochrane Library. The meta-analysis and subgroup analysis by a Bayesian logistic regression model were used to evaluate the incidences of therapy-related toxicities such as cytokine release syndrome (CRS) and neurological symptoms (NS), and the differences between different targets and cancer types were analyzed. The pooled all-grade CRS rate and grade ≥ 3 CRS rate was 77% and 29%, respectively, with a significantly higher incidence in the hematologic malignancies (all-grade: 81%; grade ≥ 3: 29%) than in solid tumors (all-grade: 37%; grade ≥ 3: 19%). The pooled estimate NS rate from the individual studies were 40% for all-grade and 28% for grade ≥ 3. It was also higher in the hematologic subgroup than in the solid tumors group. The subgroup analysis by cancer type showed that higher incidences of grade ≥ 3 CRS were observed in anti-CD19 CAR-T therapy for ALL and NHL, anti-BCMA CAR-T for MM, and anti-CEA CAR-T for solid tumors, which were between 24–36%, while higher incidences of grade ≥ 3 NS were mainly observed in CD19-ALL/NHL (23–37%) and BCMA-MM (12%). Importantly, subgroup analysis on anti-CD19 CAR-T studies showed that young patients (vs. adult patients), allologous T cell origin (vs. autologous origin), gamma retrovirus vector, and higher doses of CAR-T cells were associated with high-grade CRS. On the other hand, the patients with NHL (vs ALL), administered with higher dose of CAR-T, and adult patients (vs. young patients) had an increased incidence of grade ≥ 3 NS events. This study offers a comprehensive summary of treatment-related toxicity and will guide future clinical trials and therapeutic designs investigating CAR T cell therapy.

Identification of the Risks in CAR T-cell Therapy Clinical Trials in China: a Delphi Study.

Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors

Clinical Application and Risk Assessment of CAR-T Cell Technology in Cancer Immunotherapy

Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy

CAR-T cells: the Chinese experience

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Clinical Development of CAR T Cell Therapy in China:2020 Update

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Preliminary Assessment of Cardiotoxicity in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Systematic Review and Meta-Analysis

Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China

Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review

Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective

Immunogenicity of CAR T cells in cancer therapy

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions

CAR T-cell Therapies in China: Rapid Evolution and a Bright Future.

T-Cell Lymphomas in Recipients of CAR-T Cells: Assessing Risks and Causalities

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy